#AS­CO22: Im­bru­vi­ca keeps ag­gres­sive blood can­cer at bay for 6+ years, but miss­es the mark in over­all sur­vival

John­son & John­son and Ab­b­Vie popped the cork on some pre­lim­i­nary da­ta show­ing Im­bru­vi­ca, the orig­i­nal BTK in­hibitor, kept a rare and ag­gres­sive form of can­cer at bay in com­bi­na­tion with two oth­er drugs for more than six years. But will over­all sur­vival da­ta crash the par­ty?

Near­ly a decade af­ter win­ning a first ap­proval in sec­ond-line man­tle cell lym­phoma (MCL), J&J and Ab­b­Vie are ar­gu­ing Im­bru­vi­ca’s case in first-line pa­tients 65 years or old­er. When giv­en in com­bi­na­tion with the chemother­a­py ben­damus­tine and Rit­ux­an, Im­bru­vi­ca re­duced pa­tients’ risk of dis­ease pro­gres­sion or death by 25% com­pared to the chemo-Rit­ux­an com­bi­na­tion alone, the part­ners re­vealed on Fri­day at AS­CO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER